Drug intelligence / Profile preview

Jiling

Development stage: Preclinical
Lead developer: The Second Affiliated Hospital of Guangzhou University of Chinese Medicine
Administration: Oral

Overview

Jiling is a traditional Chinese medicine, specifically a compound herbal formulation, developed for the treatment of diarrhea-predominant irritable bowel syndrome (IBS-D). It is being investigated for its efficacy and safety in clinical trials.

Other names: Chinese medicine particles intestinal Jiling中药复方肠激灵颗粒Compound Chinese Medicine Intestinal Jiling Granules

Beyond the preview

Go deeper on Jiling.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jiling.

Explore the full profile